by Team Small News | Sep 29, 2025 | Aurobindo Pharma, Cipla, Lupin, Pharma, Sun Pharma
The Indian pharmaceutical industry is facing a complex global trade landscape, with contrasting developments in China and the US. China has reduced import duties on Indian pharma products by 30%, effectively enabling near-zero-cost access, providing a significant...
by Team Small News | Sep 27, 2025 | Cipla, Pharma, Sun Pharma
India’s generic pharmaceutical companies are likely to continue business as usual despite US President Donald Trump’s 100% levy on pharmaceuticals. The tariff is targeted at branded and patented medicines, which may not directly impact generic companies.... by Team Small News | Sep 25, 2025 | Cipla, Pharma
Bora Biologics has partnered with InvaGen Pharmaceuticals, a subsidiary of Cipla Group, to manufacture NYPOZI(TM) at its San Diego facility. This partnership marks a significant milestone in the production of NYPOZI(TM), a crucial medication for patients in need. Bora... by Team Small News | Sep 23, 2025 | Cipla, Pharma
In a significant development, Cipla, a leading pharmaceutical company, is undergoing a leadership shift. Umang Vohra, the current Managing Director and Global Chief Executive Officer (CEO), has decided to exit the company. Vohra’s departure marks the end of an... by Team Small News | Sep 22, 2025 | Cipla, Pharma
Indian pharmaceutical company Cipla is reportedly preparing for a significant management change. Umang Vohra, the company’s managing director and global CEO, is expected to step down by the end of the current fiscal year. Vohra, 54, has been in the role for... by Team Small News | Sep 20, 2025 | Cipla, Pharma
Teva Pharmaceutical Industries Ltd. has reached a settlement agreement to dismiss its patent-infringement lawsuit against Cipla Ltd., an Indian generic-drug maker, over proposed copies of its Qvar RediHaler asthma treatment. The agreement was approved by Judge Stanley...